Legend Biotech Corporation (Legend), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, raised $150 million in Series A financing. The capital infusion will go toward advancement of the research and development and commercialization of the firm’s pipeline programs and expansion of manufacturing facilities as well as general corporate expenses. Additional investors include Hudson Bay Capital Management LP, Johnson & Johnson Innovation—JJDC, Inc., Lilly Asia Ventures, Vivo Capital, RA Capital Management, and another large reputable institutional investor. The transaction was supported by investment bankers including Morgan Stanley Asia Limited and Jeffries Hong Kong Limited.
TrialSite Investor Watch breaks this firm down.
What year was the firm founded, and by whom?
The founder, Dr. Frank Zhang, founded the company in 2014 under the name GenScript Inc., which at the time was the first Chinese CAR-T therapy venture.
Where is the firm located?
The firm is headquartered in China with presence in North America (New Jersey) and Ireland.
What are their core areas ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).